The prognostic significance of p16 overexpression in oropharyngeal squamous cell carcinoma: Implications for treatment strategies and future clinical studies

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 1931-1934

  Langendijk, J A ^a   Psyrri, A ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; NIMORAZOLE; PLACEBO; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ALCOHOL CONSUMPTION; CANCER CONTROL; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; DISEASE PREDISPOSITION; DNA SEQUENCE; EDITORIAL; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCIDENCE; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; SMOKING; SOUTHERN BLOTTING; SQUAMOUS CELL CARCINOMA; WART VIRUS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957112423     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq439     Document Type: Editorial

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92(1): 4-14.
3. Bourhis J, Overgaard J, Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368(9538): 843-854.
4. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357(17): 1695-1704.
5. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005; 103(9): 1843-1849.
6. Licitra L, Zigon G, Gatta G et al. Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am 2008; 22(6): 1143-1153.
7. Gillison ML, D'Souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100(6): 407-420.
8. Wiest T, Schwarz E, Enders C et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21(10): 1510-1517.
9. de Villiers EM, Weidauer H, Otto H, zur Hausen H. Papillomavirus DNA in human tongue carcinomas. Int J Cancer 1985; 36(5): 575-578.
10. Franceschi S, Munoz N, Bosch XF et al. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996; 5(7): 567-575.
11. Snijders PJ, Scholes AG, Hart CA et al. Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinoma of the head and neck. Int J Cancer 1996; 66(4): 464-469.
12. Franceschi S, Munoz N, Bosch XF et al. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996; 5(7): 567-575.
13. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24(5): 736-747.
14. Fischer CA, Kampmann M, Zlobec I et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol 2010; 21: 1961-1966.
15. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010; 116(9): 2166-2173.
16. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363(1): 24-35.
17. Smeets SJ, Hesselink AT, Speel EJ et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121(11): 2465-2472.
18. Lassen P, Eriksen JG, Hamilton-Dutoit S et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27(12): 1992-1998.
19. Sedaghat AR, Zhang Z, Begum S et al. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 2009; 119(8): 1542-1549.
20. Fischer CA, Zlobec I, Green E et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 2010; 126(5): 1256-1262.
21. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100(4): 261-269.
22. de Jong MC, Pramana J, Knegjens JL et al. HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. Radiother Oncol 2010; 95(3): 365-370.
23. Lassen P, Eriksen JG, Tramm T et al. HPV-associated p16-expression and response to radiobiological modifications of radiotherapy in head and neck cancer: results from the randomised DAHANCA trials. Euro J Cancer Suppl 7: 2009; 11 (Abstr).
24. Nguyen-Tan P, Pajak TF, Wheeler R et al. A phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): report of efficacy and toxicity. In Proceedings of the Multidisciplinary Head and Neck Cancer Symposium. ECCO ESMO 2010 Berlin, Chandler Arizona, February 25-27 (Abstr). 2010.